An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: Case example dantrolene

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 200-207

  Kambayashi, Atsushi ^a,b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Biorelevant media; Dantrolene; Oral administration; Pharmacokinetics; Precipitation

Indexed keywords

DANTROLENE; SODIUM;

ARTICLE; CALCULATION; COMPUTER MODEL; COMPUTER PROGRAM; DIET RESTRICTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRECIPITATION; PREDICTION;

ADMINISTRATION, ORAL; COMPUTER SIMULATION; DANTROLENE; FORECASTING; GASTRIC EMPTYING; HUMANS; MALE; MODELS, BIOLOGICAL; SALTS; SOLUBILITY;

EID: 84876943420     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.12.001     Document Type: Article

References (29)

1. L. Di, E.H. Kerns, and G.T. Carter Drug-like property concepts in pharmaceutical design Curr. Pharm. Des. 15 2009 2184 2194
2. A.T. Serajuddin Salt formation to improve drug solubility Adv. Drug Deliv. Rev. 59 2007 603 616
3. A. Fahr, and X. Liu Drug delivery strategies for poorly water-soluble drugs Expert Opin. Drug Deliv. 4 2007 403 416
4. D.B. Warren, H. Benameur, C.J. Porter, and C.W. Pouton Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility J. Drug Target. 18 2010 704 731
5. H.R. Guzman, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.P. Moreau, O. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 96 2007 2686 2702
6. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
7. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Eur. J. Pharm. Biopharm. 76 2010 95 104
8. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, and J.B. Dressman Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 73 2009 107 114
9. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
10. G. Valsami, A. Dokoumetzidis, and P. Macheras Modeling of supersaturated dissolution data Int. J. Pharm. 181 1999 153 157
11. K. Sugano A simulation of oral absorption using classical nucleation theory Int. J. Pharm. 378 2009 142 145
12. K. Sugano Computational oral absorption simulation of free base drugs Int. J. Pharm. 398 2010 73 82
13. G. Charkoftaki, A. Dokoumetzidis, G. Valsami, and P. Macheras Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case J. Pharm. Pharmacol. 63 2011 352 361
14. Y.E. Arnold, G. Imanidis, and M.T. Kuentz Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model J. Pharm. Pharmacol. 63 2011 333 341
15. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
16. S. Carlert, P. Akesson, G. Jerndal, L. Lindfors, H. Lennernas, and B. Abrahamsson In vivo dog intestinal precipitation of mebendazole: a basic BCS class II drug Mol Pharm 9 2012 2903 2911
17. A. Mattei, and T. Li Polymorph formation and nucleation mechanism of tolfenamic acid in solution: an investigation of pre-nucleation solute association Pharm. Res. 29 2012 460 470
18. T.M. Gilman, J.L. Segal, and S.R. Brunnemann Metoclopramide increases the bioavailability of dantrolene in spinal cord injury J. Clin. Pharmacol. 36 1996 64 71
19. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417
20. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
21. S. Klein, and V.P. Shah A standardized mini paddle apparatus as an alternative to the standard paddle AAPS PharmSciTech 9 2008 1179 1184
22. T. Podranski, T. Bouillon, P.M. Schumacher, A. Taguchi, D.I. Sessler, and A. Kurz Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth. Analg. 101 2005 1695 1699
23. P. Macheras, C. Reppas, and J. Dressman Biopharmaceutics of Orally Administered Drugs 1995 Ellis Horwood Ltd. London
24. C. Schiller, C.P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 22 2005 971 979
25. A.W. Basit, J.M. Newton, M.D. Short, W.A. Waddington, P.J. Ell, and L.F. Lacey The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs Pharm. Res. 18 2001 1146 1150
26. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test Pharm. Res. 23 2006 1144 1156
27. L.X. Yu An integrated model for determining causes of poor oral drug absorption Pharm. Res. 16 1999 1883 1887
28. V.P. Shah, L.J. Lesko, J. Fan, N. Fleischer, J. Handerson, H. Malinowski, M. Makary, L. Ouderkirk, S. Roy, P. Sathe, G.J.P. Singh, L. Tillman, Y. Tsong, and R.I. Williams FDA guidance for industry: dissolution testing of immediate release solid oral dosage forms Dissol. Technol. 4 1997 15 22
29. L. Fynne, J. Worsoe, T. Gregersen, V. Schlageter, S. Laurberg, and K. Krogh Gastric and small intestinal dysfunction in spinal cord injury patients Acta Neurol. Scand. 125 2012 123 128